Regulation of Inflammation-Related Genes through Fosl1 Suppression in a Levetiracetam-Treated Pilocarpine-Induced Status Epilepticus Mouse Model
Open Access
- 9 July 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (14) , 7608
Abstract
Levetiracetam (LEV) suppresses the upregulation of proinflammatory molecules that occurs during epileptogenesis after status epilepticus (SE). Based on previous studies, LEV likely helps prevent the onset of epilepsy after insults to the brain, unlike other conventional anti-epileptic drugs. Recently, we discovered that the increase in Fosl1 expression that occurs after lipopolysaccharide (LPS) stimulation is suppressed by LEV and that Fosl1 inhibition suppresses inflammation in BV-2 microglial cells. These data indicate that Fosl1 is an important target of LEV and a key factor in preventing epilepsy onset. In this study, we examined the effects of LEV on Fosl1 expression and neuroinflammation in vivo. During epileptogenesis, the post-SE upregulation of hippocampal levels of Fosl1 and many inflammatory factors were suppressed by LEV. Fosl1 expression showed a characteristic pattern different from that of the expression of Fos, an immediate-early gene belonging to the same Fos family. At 2 days after SE, Fosl1 was predominantly expressed in astrocytes but was rarely detected in microglia, whereas Fos expression was distributed in various brain cell types. The expression of A2 astrocyte markers was similar to that of Fosl1 and was significantly suppressed by LEV. These results suggest that LEV may regulate astrocyte reactivity through regulation of Fosl1.Keywords
Funding Information
- Japan Society for the Promotion of Science (15K18947, 17K15533, 17H04714, 20H04341, 17K08356, 21K06702)
This publication has 49 references indexed in Scilit:
- Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsyEpilepsia, 2013
- Finding a better drug for epilepsy: The mTOR pathway as an antiepileptogenic targetEpilepsia, 2012
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012
- Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2Proceedings of the National Academy of Sciences, 2012
- The Role of Astroglia in the Epileptic BrainFrontiers in Pharmacology, 2012
- Astroglial Networks and Implications for Therapeutic Neuromodulation of EpilepsyFrontiers in Computational Neuroscience, 2012
- Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational studyEpilepsy Research, 2008
- Adult epilepsyThe Lancet, 2006
- GABA receptor function and pharmacology in epilepsy and status epilepticusCurrent Opinion in Pharmacology, 2003
- DNA Fragmentation and Prolonged Expression of c-fos, c-jun, and hsp70 in Kainic Acid-Induced Neuronal Cell Death in Transgenic Mice Overexpressing Human CuZn-Superoxide DismutaseJournal of Cerebral Blood Flow & Metabolism, 1997